ERBB2 and breast cancer: Patients with HER2+ BC were more frequently diagnosed with asymptomatic BM during staging procedures (65/230;28.3%), compared to HR+ BC (47/260; 18.1%) and TN-BC (24/163; 14.7%; chi-square test; p = 0.002; Supplementary Table 2; Fig. 1d).